Two items recently perused have, in their own separate ways, set me thinking about a debate that should be taking place, but isn't. No, strike debate, it should be a struggle for the hearts and souls of academic scientists. At issue are the behavioral norms that guide the research community. In the red corner, see the Oct. 9 leader (editorial) in the British newspaper The Guardian. Under the title "Patent Justice," the piece applauds the award of the Nobel Prize to John Sulston, and continues

The "big three" journals, Nature, Science, and Cell, undoubtedly have some say in the development and perception of science. But what exactly is their impact? How long-lasting is it? Is it helpful or damaging? The story on page 59 of this issue considers how competition among these journals for high-profile breakthroughs may harm the scientific process, and another on page 76 profiles one of the architects of the current state of affairs. Is it now time, in the best interests of science, to d

The ability to name is surely one of the great intellectual leaps of humankind. This is vividly illustrated in an extract of the uplifting poetry of the Kato Indians, an account of genesis: "Woodpeckers were not they say. Then wrens were not they say. Then hummingbirds were not they say. Then otters were not they say. Then jackrabbits, grey squirrels were not they say ... Then clouds were not they say. Fog was not they say. It didn't appear they say. Stars were not they say. It was very dark."

The UK government is currently espousing a passion for science. Prime Minister Tony Blair said recently: "The strength and creativity of our science base is a key national asset as we move into the 21st century." And the minister for science and technology, David Sainsbury, recently remarked: "It (science) can improve the quality of our lives by enabling us to live more healthily, and longer". Exactly so. Demonstrating this new attitude, Blair's government has significantly boosted the United

Self-renewal and the capacity to differentiate into a multitude of mature cell types have made stem cells the hottest ticket in biomedicine. But there are questions aplenty, scientific and otherwise. Do we need more stem cell lines? President Bush may believe that the available lines are sufficient, but these are derived fro1m blastocysts produced in fertility clinics. Maximizing the impact of stem cells in medicine calls for new lines derived from specific diseases, like cancers. Must thera

Open Access, High Ambitions By Richard Gallagher   Fueled by scientists' resentment at perceived exploitation by established publishers, and driven by new opportunities in information technology, open access publishing burst onto the scene in biomedicine about five years ago. Most readers of The Scientist will be aware of the principal, two-part, argument in its favor, namely that: Maximum dissemination of properly peer-reviewed research is good for authors, good for funders, and, mos